High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance.

@article{Garabedian2013HighRP,
  title={High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance.},
  author={Torkom Garabedian and Samir Alam},
  journal={Cardiovascular diagnosis and therapy},
  year={2013},
  volume={3 1},
  pages={23-37}
}
Over the last decade, dual antiplatelet therapy has been the mainstay of the management of Acute Coronary Syndrome, with clopidogrel therapy providing clear benefits over aspirin monotherapy and becoming the agent of choice for the prevention of stent thrombosis. While newer antiplatelet agents have now become available, clopidogrel is still widely used due to its low cost and efficacy. However, many patients still experience recurrent ischemic events. A poor response of the platelets to… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation • 2016
View 8 Excerpts
Highly Influenced

The Rationale for and Clinical Pharmacology of Prasugrel 5 mg.

American journal of cardiovascular drugs : drugs, devices, and other interventions • 2017
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 68 references

Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty - Platelet Reactivity Predicts Outcome ) study

W Hochholzer, D Trenk, HP Bestehorn
Cardiovasc Diagn Ther • 2013

Similar Papers

Loading similar papers…